Emerging pharmacotherapy for cancer patients with cognitive dysfunction

被引：28

作者：

Davis, Justin ^{[1
]}

Ahlberg, Fiona M. ^{[1
]}

Berk, Michael ^{[1
,3
,4
]}

Ashley, David M. ^{[1
,2
]}

Khasraw, Mustafa ^{[1
,2
,5
]}

机构：

[1] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia

[2] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic 3220, Australia

[3] Univ Melbourne, Dept Psychiat, Orygen Youth Hlth, Parkville, Vic 3052, Australia

[4] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia

[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

来源：

BMC NEUROLOGY | 2013年 / 13卷

关键词：

Cancer; Cognitive impairment; Chemotherapy; Cognitive dysfunction; Pharmacotherapy; CROSS-OVER TRIAL; QUALITY-OF-LIFE; BREAST-CANCER; DOUBLE-BLIND; ALZHEIMERS-DISEASE; CHILDHOOD-CANCER; CRANIAL IRRADIATION; RAT-BRAIN; CHEMOTHERAPY; METHYLPHENIDATE;

D O I：

10.1186/1471-2377-13-153

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of memory and cognition, with ramifications for the patient's mood and other cognition disorders. Similarly radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer's drugs memantine and donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture models to evaluate their use in treating cognitive dysfunction.

引用

页数：9